Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion. The studies had to have a minimum sample size of 50.
Specific interventions included in the review
Studies of bevacizumab therapy in addition to chemotherapy or no therapy were eligible for inclusion. Concurrent chemotherapy included fluorouracil and leucovorin, irinotecan, fluorouracil and leucovorin, carboplatin and paclitaxel, capecitabine, gemcitabine and cisplatin.
Participants included in the review
Studies assessing patients with metastatic cancer were eligible for inclusion. The patients included in the review were being treated for colorectal, renal, non-small-cell lung, breast and malignant mesothelimona cancers. Renal function was described as normal or adequate, and creatinine levels were reported as being less than 2.0 mg/dL in 2 studies. The proportion of patients undergoing previous chemotherapy ranged from 0 to 100%.
Outcomes assessed in the review
Studies assessing proteinuria and hypertension were eligible for inclusion. Clinical end points were recorded according to the National Cancer Institute Common Toxicity Criteria, version I or II, and were recorded for both proteinuria and hypertension as grades I to IV.
How were decisions on the relevance of primary studies made?
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.